RenovoRx rises on positive data from pancreatic cancer therapy study

RenovoRx

29/06/2023 15:46

(Updates)
    ** Shares of drug developer RenovoRx  RNXT.O  rise 28% to
hit of $2.86, an over one-month high 
        **  Stock set for biggest one-day pct gain in 3 months,
if gains hold  
    ** Co says its experimental therapy to treat advanced 
pancreatic cancer delayed disease progression, according to
interim data from a late-stage study   
    ** The therapy, RenovoGem, delayed cancer progression by 15
months compared to 7 months in standard-of-care treatment- RNXT
    ** RenovoGem is RNXT's first drug-device combination product
candidate that utilizes company's therapy platform to deliver an
FDA-approved chemotherapy
    ** Including session's move, stock up ~29% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))